FDA
-
-
-
-
-
-
-
Creative Medical Technology shares shareholder letter on clinical progress
-
-
-
-
-
-
-
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using Al
-
-
-
-
-
-
-
Creative Medical Technology Holdings (CELZ) Issues Corporate Update
-
-
-
-
-
-
-
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
-
-
-
-
-
-
-
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
-
-
-
-
-
-
-
Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes
-
-
-
-
-
-
-
Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

